Company Description
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.
It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.
It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments.
It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026.
Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Michael Halstead |
Contact Details
Address: 100 King Street West, Suite 5600 Toronto, ON M5X 1C9 Canada | |
| Phone | 908 764 8385 |
| Website | helus.com |
Stock Details
| Ticker Symbol | HELP |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1833141 |
| CUSIP Number | 423492107 |
| ISIN Number | CA4234921076 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael I. Halstead J.D. | Chief Executive Officer and Director |
| Eric So L.L.B. | Co-Founder, President and Executive Chairman |
| Paul Glavine | Co-Founder, Chief Growth Officer and Director |
| Greg Cavers | Chief Financial Officer |
| Aaron Bartlone | Chief Operating Officer |
| Dr. Amir Inamdar FFPM, MBBS | Chief Medical Officer |
| John Kanakis | Co-Founder |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Lori Challenger | Chief Compliance, Ethics and Administrative Officer |
| Gabriel Fahel | Chief Legal Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 6-K | Report of foreign issuer |
| Oct 8, 2026 | 6-K | Report of foreign issuer |
| Oct 5, 2026 | 6-K | Report of foreign issuer |
| Oct 2, 2026 | 6-K | Report of foreign issuer |
| Oct 1, 2026 | 6-K | Report of foreign issuer |
| Sep 23, 2026 | 6-K | Report of foreign issuer |
| Sep 22, 2026 | 6-K | Report of foreign issuer |
| Sep 21, 2026 | 6-K | Report of foreign issuer |
| Sep 10, 2026 | 6-K | Report of foreign issuer |
| Sep 9, 2026 | SCHEDULE 13D | Filing |